Known targets — ChEMBL curated mechanism
FGFR1FGFR2FGFR3FGFR4KDRPDGFRAPDGFRB
The experimentally established mechanism targets of Orantinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 known ✓ | P11362 | 16/20 | 1.00 |
| ▸ | KDR known ✓ | P35968 | 16/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 16/20 | 1.00 |
| ▸ | FGFR3 known ✓ | P22607 | 1/20 | 1.00 |
| ▸ | FLT1 | P17948 | 3/20 | 1.00 |
| ▸ | AURKA | O14965 | 2/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
| ▸ | FLT3 | P36888 | 2/20 | 1.00 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 1.00 |
| ▸ | STK3 | Q13188 | 2/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 2/20 | 1.00 |
| ▸ | ZAP70 | P43403 | 2/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 1.00 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 1.00 |
| ▸ | LATS1 | O95835 | 1/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 1.00 |
| ▸ | MAP2K2 | P36507 | 1/20 | 1.00 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 1.00 |
| ▸ | STK4 | Q13043 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Orantinib SCHEMBL134662 | 1.00 | FGFR1 (1.00) | FGFR1KDRPDGFRBFLT1AURKA | |
| Orantinib SCHEMBL900355 | 1.00 | FGFR1 (1.00) | FGFR1KDRPDGFRBFLT1AURKA | |
| Orantinib SCHEMBL29354645 | 1.00 | FGFR1 (1.00) | FGFR1KDRPDGFRBFLT1AURKA | |
| SCHEMBL12020869 | 0.91 | KDR (0.84) | FGFR1KDRPDGFRBFLT1AURKA | |
| SCHEMBL25717271 | 0.90 | KDR (0.82) | FGFR1KDRPDGFRBFLT1AURKA | |
| SCHEMBL26023377 | 0.88 | KDR (0.79) | FGFR1KDRPDGFRBFLT1AURKA | |
| SCHEMBL13497857 | 0.88 | KDR (0.79) | FGFR1KDRPDGFRBFLT1AURKA | |
| SCHEMBL4408686 | 0.88 | KDR (1.00) | FGFR1KDRPDGFRBFLT1AURKA | |
| SCHEMBL29678231 | 0.88 | KDR (1.00) | FGFR1KDRPDGFRBFLT1AURKA | |
| SCHEMBL30676938 | 0.88 | KDR (1.00) | FGFR1KDRPDGFRBFLT1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 310 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11331272-B2 | Hyperstabilized liposomes increase targeting of mitotic cells | TEMASEK LIFE SCIENCES LABORATORY LIMITED (SG) | 2022-05-17 | — | — | US | claimed |
| EP-3400210-B1 | \"MULTI-TARGET\" COMPOUNDS WITH INHIBITORY ACTIVITY TOWARDS HISTONE DEACETYLASES AND TUBULIN POLYMERISATION, FOR USE IN THE TREATMENT OF CANCER | UNIV PARIS SACLAY (FR) | 2021-09-29 | — | — | EP | claimed |
| US-11014871-B2 | “Multi-target” compounds with inhibitory activity towards histone deacetylases and tubulin polymerisation, for use in the treatment of cancer | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2021-05-25 | — | — | US | claimed |
| US-10744141-B2 | Compositions and methods for treating cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-08-18 | — | — | US | claimed |
| WO-2019057920-A1 | BORONATE ESTER CROSSLINKED NANOGELS BASED ON MODIFIED POLYSACCHARIDES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2019-03-28 | — | — | WO | claimed |
| EP-2142493-B1 | ISO CA-4 AND ANALOGUES THEREOF AS POTENT CYTOTOXIC AGENTS INHIBITING TUBULINE POLYMERISATION | CENTRE NAT RECH SCIENT (FR) | 2019-03-27 | — | — | EP | claimed |
| US-20190023645-A1 | \"MULTI-TARGET\" COMPOUNDS WITH INHIBITORY ACTIVITY TOWARDS HISTONE DEACETYLASES AND TUBULIN POLYMERISATION, FOR USE IN THE TREATMENT OF CANCER | UNIVERSITE PARIS-SUD (FR) | 2019-01-24 | — | — | US | claimed |
| EP-3400210-A2 | \"MULTI-TARGET\" COMPOUNDS WITH INHIBITORY ACTIVITY TOWARDS HISTONE DEACETYLASES AND TUBULIN POLYMERISATION, FOR USE IN THE TREATMENT OF CANCER | Universite Paris-Sud (FR) | 2018-11-14 | — | — | EP | claimed |
| EP-2786765-B1 | Composition for combination therapy comprising an anti-C-met antibody and a FGFR inhibitor | SAMSUNG ELECTRONICS CO LTD (KR) | 2018-10-03 | — | — | EP | claimed |
| US-20180185382-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CASE WESTERN RESERVE UNIVERSITY | 2018-07-05 | — | — | US | claimed |
| US-20040018528-A1 | Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals | SUGEN, INC. | 2004-01-29 | — | — | US | claimed |
| WO-2003097854-A2 | NOVEL BIOMARKERS OF TYROSINE KINASE INHIBITOR EXPOSURE AND ACTIVITY IN MAMMALS | SUGEN, INC. (US) | 2003-11-27 | — | — | WO | claimed |
| US-20030105151-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. | 2003-06-05 | — | — | US | claimed |
| US-20020119198-A1 | Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs | PHARMACIA & UPJOHN COMPANY | 2002-08-29 | — | — | US | claimed |
| EP-1233943-A2 | IONIZABLE INDOLINONE DERIVATIVES AND THEIR USE AS PTK LIGANDS | Sugen, Inc. (US) | 2002-08-28 | — | — | EP | claimed |
| US-6395734-B1 | ANTICANCER AGENTS | SUGEN, INC. | 2002-05-28 | — | — | US | claimed |
| WO-2001037820-A2 | IONIZABLE INDOLINONE DERIVATIVES AND THEIR USE AS PTK LIGANDS | SUGEN, INC. (US) | 2001-05-31 | — | — | WO | claimed |
| EP-1066257-A2 | HETEROCYLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | Sugen, Inc. (US) | 2001-01-10 | — | — | EP | claimed |
| WO-1999048868-A9 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN INC (US) | 2000-04-20 | — | — | WO | claimed |
| WO-1999048868-A2 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN, INC. (US) | 1999-09-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105151-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | DMPK, PDPK1, PLK2 | FGFR1 930/4885KDR 1066/4885PDGFRB 1086/4885 |
| US-20180185382-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | PPP2CA, PPP3CA, PPP4C | FGFR1 3484/4885KDR 4298/4885PDGFRB 2913/4885 |
| US-10744141-B2 | Compositions and methods for treating cancer | PPP2CA, PPP3CA, PPP4C | FGFR1 3484/4885KDR 4298/4885PDGFRB 2913/4885 |
| US-20020119198-A1 | Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs | LIPA, ABCG2, LIPG | FGFR1 3688/4885KDR 1068/4885PDGFRB 2114/4885 |
| US-20190023645-A1 | \"MULTI-TARGET\" COMPOUNDS WITH INHIBITORY ACTIVITY TOWARDS HISTONE DEACETYLASES AND TUBULIN POLYMERISATION, FOR USE IN THE TREATMENT OF CANCER | HDAC6, HDAC1, HDAC5 | FGFR1 995/4885KDR 3137/4885PDGFRB 1927/4885 |
| US-11014871-B2 | “Multi-target” compounds with inhibitory activity towards histone deacetylases and tubulin polymerisation, for use in the treatment of cancer | HDAC6, HDAC1, HDAC5 | FGFR1 1186/4885KDR 3315/4885PDGFRB 1953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.